文献速递类风湿关节炎

JAK抑制剂与其他免疫调节药物治疗类风湿关节炎患者的静脉血栓栓塞:瑞典比较安全性研究

Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2022-09-23

这项瑞典全国性注册队列研究纳入2010至2021年32 737次治疗启动,比较JAK抑制剂、TNF抑制剂与非TNF生物制剂在类风湿关节炎患者中的静脉血栓栓塞发生率。JAK抑制剂组年龄性别标化发生率为11.33/1000人年,TNF抑制剂组为5.15/1000人年;完全校正后JAK抑制剂对比TNF抑制剂的静脉血栓栓塞HR为1.73(95%CI 1.24至2.42),肺栓塞HR为3.21(95%CI 2.11至4.88),深静脉血栓HR为0.83(95%CI 0.47至1.45)。

要点

  • JAK抑制剂组静脉血栓栓塞标化发生率为11.33/1000人年,TNF抑制剂组为5.15/1000人年。
  • JAK抑制剂对比TNF抑制剂的静脉血栓栓塞完全校正HR为1.73(95%CI 1.24至2.42)。
  • 风险增加在数值上局限于肺栓塞,其HR为3.21(95%CI 2.11至4.88),深静脉血栓HR为0.83(95%CI 0.47至1.45)。

核心结论

  • 在临床实践中,接受JAK抑制剂治疗的类风湿关节炎患者相比接受bDMARDs治疗者静脉血栓栓塞风险增加,该增加在数值上局限于肺栓塞。

研究设计与样本

  • 瑞典全国性注册、活性对照、新使用者设计队列研究,时间范围为2010年至2021年。
  • 瑞典风湿病质量登记与国家健康登记链接,识别JAK抑制剂、TNF抑制剂或非TNF bDMARDs启动者治疗队列,共32 737次治疗启动。
  • 另识别一般人群队列(1:5匹配,n=92 108)和「总体类风湿关节炎」对照队列(n=85 722)。
  • 结局为随访期间首次静脉血栓栓塞时间,总体及按深静脉血栓和肺栓塞分别分析。
  • 计算发生率(IR)并使用Cox回归计算多变量校正HR。

主要发现

  • 基于559例 incident 静脉血栓栓塞事件,年龄性别标化(以TNF抑制剂为参照)的静脉血栓栓塞IR(95%CI)为:TNF抑制剂治疗患者5.15/1000人年(4.58至5.78),JAK抑制剂治疗患者11.33/1000人年(8.54至15.04),总体类风湿关节炎队列5.86/1000人年(5.69至6.04),一般人群3.28/1000人年(3.14至3.43)。
  • JAK抑制剂对比TNF抑制剂的静脉血栓栓塞完全校正HR(95%CI)为1.73(1.24至2.42)。
  • JAK抑制剂对比TNF抑制剂的肺栓塞HR(95%CI)为3.21(2.11至4.88),深静脉血栓HR(95%CI)为0.83(0.47至1.45)。

关键数值与推荐

  • JAK抑制剂对比TNF抑制剂的静脉血栓栓塞完全校正HR为1.73(95%CI 1.24至2.42)。
  • JAK抑制剂对比TNF抑制剂的肺栓塞HR为3.21(95%CI 2.11至4.88)。
  • JAK抑制剂对比TNF抑制剂的深静脉血栓HR为0.83(95%CI 0.47至1.45)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess and compare the incidence of venous thromboembolism (VTE) in patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKi), tumour necrosis factor inhibitors (TNFi) or other biological disease modifying antirheumatic drugs (bDMARDs). For contextualisation, to assess VTE incidences in the Swedish general population and in the RA source population. METHODS: We performed a nationwide register-based, active comparator, new user design cohort study in Sweden from 2010 to 2021. The Swedish Rheumatology Quality Register was linked to national health registers to identify treatment cohorts (exposure) of initiators of a JAKi, a TNFi, or a non-TNFi bDMARD (n=32 737 treatment initiations). We also identified a general population cohort (matched 1:5, n=92 108), and an 'overall RA' comparator cohort (n=85 722). Outcome was time to first VTE during the follow-up, overall and by deep vein thrombosis (DVT) and pulmonary embolism (PE). We calculated incidence rates (IR) and multivariable-adjusted HRs using Cox regression. RESULTS: Based on 559 incident VTE events, the age- and sex-standardised (to TNFi) IR (95% CI) for VTE was 5.15 per 1000 person-years (4.58 to 5.78) for patients treated with TNFi, 11.33 (8.54 to 15.04) for patients treated with JAKi, 5.86 (5.69 to 6.04) in the overall RA cohort and 3.28 (3.14 to 3.43) in the general population. The fully adjusted HR (95% CI) for VTE with JAKi versus TNFi was 1.73 (1.24 to 2.42), the corresponding HR for PE was 3.21 (2.11 to 4.88) and 0.83 (0.47 to 1.45) for DVT. CONCLUSIONS: Patients with RA treated with JAKi in clinical practice are at increased risk of VTE compared with those treated with bDMARDs, an increase numerically confined to PE.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Molander V, Bower H, Frisell T, et al. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. 2022. PMID: 36150749. doi:10.1136/ard-2022-223050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。